Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease

•Interstitial lung disease (ILD) is potentially life-threatening event related with crizotinib.•Incidence of crizotinib-related ILD was 1.2% and predisposing factors are unknown.•Crizotinib rechallenge should be considered only in mild cases of ILD.•Switching treatment to other ALK inhibitors was re...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2018-05, Vol.119, p.99-102
Main Authors: Doménech, Marta, Jové, Maria, Aso, Samantha, Marín, Mar, Nadal, Ernest
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
ALK positive
Anaplastic Lymphoma Kinase - antagonists & inhibitors
Anaplastic Lymphoma Kinase - genetics
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Crizotinib - adverse effects
Crizotinib - therapeutic use
Drug Substitution
Female
Gene Rearrangement
Humans
Interstitial lung disease
Lung adenocarcinoma
Lung Diseases, Interstitial - etiology
Lung Diseases, Interstitial - prevention & control
Lung Neoplasms - drug therapy
Lung toxicity
Middle Aged
Neoplasm Metastasis
Oncogene Proteins, Fusion - genetics
Organophosphorus Compounds - therapeutic use
Pyrimidines - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Interstitial lung disease (ILD) is potentially life-threatening event related with crizotinib.•Incidence of crizotinib-related ILD was 1.2% and predisposing factors are unknown.•Crizotinib rechallenge should be considered only in mild cases of ILD.•Switching treatment to other ALK inhibitors was reported without ILD recurrence. We present a 45-year-old patient diagnosed with anaplastic lymphoma kinase (ALK)-rearranged metastatic lung cancer who developed grade 4 interstitial lung disease (ILD) while on crizotinib treatment and was lately treated with brigatinib with no reappearance of ILD. To our knowledge, this is the first case report of successful treatment with brigatinib after crizotinib-induced ILD. Even though ILD secondary to brigatinib has been reported in clinical trials, no pulmonary toxicity has been seen in our patient, suggesting no crosslink lung toxicity between crizotinib and brigatinib.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2018.03.014